Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
bluebird bio (BLUE)
NASDAQ:BLUE
Bluebird Bio (BLUE) Stock Price & Analysis
2,597 Followers
BLUE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.85 - $5.53
Previous Close$0.91
Volume3.54M
Average Volume (3M)6.22M
Market Cap
$177.92M
Enterprise Value$307.33M
Total Cash (Recent Filing)$174.29M
Total Debt (Recent Filing)$303.71M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Aug 06, 2024EPS Estimate
-$0.46Last Dividend Ex-Date
Nov 05, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding109,336,211
10 Day Avg. Volume6,501,274
30 Day Avg. Volume6,217,117
Standard Deviation0.21
R-Squared0.05
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.46
Price to Sales (P/S)27.33
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.65
Enterprise Value/Gross Profit-47.43
Enterprise Value/Ebitda-3.07
Forecast
1Y Price Target
$5.00Price Target Upside446.87% Upside
Rating ConsensusHold
Number of Analyst Covering6
Bluebird Bio News
PremiumCompany Announcements
Bluebird Bio Welcomes Michael Cloonan to Board of Directors
PremiumCompany Announcements
Bluebird Bio Announces CFO Transition and Compensation Details
PremiumStock Analysis & Ideas
BLUE vs. CRSP: Why Are These Stocks Moving in Opposite Directions?
Bulls Say, Bears Say
Bulls Say
Clinical TrialsBLUE has initiated a trial in patients aged 2 to 12 for label expansion of Lyfgenia.
Financial PerformanceProduct revenue for the first quarter was $18.6 million, up 138% quarter-over-quarter.
Product LaunchManagement reiterated expectations for sufficient capacity to meet launch expectations for Lyfgenia and plans to scale as demand increases.
Bears Say
Cash FlowBears point to lack of visibility on path to cash flow breakeven (in part due to ongoing financial restatement).
EarningsBLUE reported 1Q EPS and total net sales of $18.6mn below consensus estimates of $22.5mn/$26.8mn.
Financial PerformanceBLUE continues to work through restatement of 2022/23 financials for treatment of leases – which has delayed its FY23 10-K and 1Q24 10-Q – but did not provide any specific timelines on when.
---
Ownership Overview
4.95% Insiders
14.60% Mutual Funds
24.73% Other Institutional Investors
55.73% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BLUE FAQ
What was bluebird bio’s price range in the past 12 months?
bluebird bio lowest stock price was $0.84 and its highest was $5.53 in the past 12 months.
What is bluebird bio’s market cap?
Currently, no data Available
When is bluebird bio’s upcoming earnings report date?
bluebird bio’s upcoming earnings report date is Aug 06, 2024 which is in 33 days.
How were bluebird bio’s earnings last quarter?
bluebird bio released its earnings results on May 09, 2024. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.441 by -$0.019.
Is bluebird bio overvalued?
According to Wall Street analysts bluebird bio’s price is currently Undervalued.
Does bluebird bio pay dividends?
bluebird bio pays a Notavailable dividend of $8.88 which represents an annual dividend yield of N/A. See more information on bluebird bio dividends here
What is bluebird bio’s EPS estimate?
bluebird bio’s EPS estimate is -$0.46.
How many shares outstanding does bluebird bio have?
bluebird bio has 192,741,940 shares outstanding.
What happened to bluebird bio’s price movement after its last earnings report?
bluebird bio reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.441. Following the earnings report the stock price went up 15.464%.
Which hedge fund is a major shareholder of bluebird bio?
Among the largest hedge funds holding bluebird bio’s share is Woodline Partners LP. It holds bluebird bio’s shares valued at 1M.
---
Bluebird Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.00 (446.87% Upside)
$5.00 (446.87% Upside)
Blogger Sentiment
Bullish
BLUE Sentiment 81%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
bluebird bio
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
---
BLUE Earnings Call
Q1 2024
0:00 / 0:00
---
BLUE Stock 12 Month Forecast
Average Price Target
$5.00
▲(446.87% Upside)
Technical Analysis
Best Analysts Covering BLUE
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+8.60%
reiterated a sell rating 2 months ago
Copying Salveen Richter's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +8.60% per trade.
---